What is the current valuation of VIOS based on this deck?

Based on Slide 9, VIOS is asking for $120,000 in exchange for 15% equity. This calculation suggests a pre-money valuation of approximately $680,000 and a post-money valuation of $800,000. This is a typical range for a pre-seed startup with early traction but a product still in the integration phase.

How many active users does the platform currently have?

According to Slide 6, the platform has 170+ registered doctors, but only 46 are listed as 'Active Doctor profiles.' Additionally, there are 2,400+ patient profiles. However, a footnote indicates these users are currently dormant while waiting for the ViOS 2.0 integration, suggesting the platform is in a transition period.

What specific problems does VIOS aim to solve for doctors?

Slide 4 and Slide 8 outline the core benefits: reducing operational expenses, travel time, and exposure risks. It also aims to help healthcare providers manage 'burn rate' and establish 'safe secure scalable operations.' The goal is to make the health sector behave more like a startup in terms of efficiency.

What technical capabilities are built into the VIOS platform?

Slide 5 lists several 'Technical Capacity' features including end-to-end user profile generation, encrypted login, on-demand video call initiation, attendance tracking, automated session recording, a data cloud link, text functions for prescriptions, and mobile financial services.

VIOS Pitch Deck (2020): 29-Slide Pre-Seed Deck

See all 29 slides of the VIOS pitch deck — a 2020 Pre Seed deck — with a slide-by-slide teardown of what the deck does well and where it falls short.

VIOS is a healthtech SaaS startup positioning itself as a solution for rapid, safe doctor-patient engagements. The deck highlights a transition from a '1.0' platform to a '2.0' integration, reporting a base of 170+ registered doctors and 2,400+ patient profiles as of March 2020. The startup emphasizes cost reduction and operational scalability as its primary value drivers. Seeking a $120,000 investment in exchange for 15% equity, the proposal is aimed at pre-seed or angel investors, with funds earmarked for technical upgrades, cybersecurity, and B2B expansion. While the deck provides a clear…

Key takeaways

The company is seeking a $120,000 investment in exchange for 15% equity, implying an $800,000 post-money valuation (Slide 9).
Traction data from October 2019 to March 2020 shows 170+ registered doctors and 2,400+ patient profiles (Slide 6).
A significant portion of the current user base is described as 'dormant,' awaiting the launch of the ViOS 2.0 platform (Slide 6).
The platform includes specific technical features such as encrypted secure remote login, automated session recording, and mobile financial services (Slide 5).
Market context points to a 19.4% average annual growth in internet subscriptions since 2012, with a surge in 2020 online healthcare activity (Slide 3).
The value proposition centers on reducing operational expenses, travel costs, and exposure risks for healthcare providers (Slide 4).
The investment ask includes non-monetary 'support requirements' such as mentorship, leadership training, and B2B access points (Slide 9).
The company has established a B2B partnership for telehealth development with an entity named Orbis (Slide 7).

VIOS Pitch Deck Analysis

The VIOS pitch deck is a straightforward, early-stage presentation focused on the burgeoning telehealth sector. It positions the company as a necessary bridge for the healthcare industry to adopt 'startup-like' efficiencies. The deck relies heavily on the timing of the 2020 pandemic to justify the immediate need for its 2.0 platform integration.

Slide 1: Title Slide

The cover slide is minimalist, featuring the company name 'VIOS' and the tagline 'See your Doctor Quickly | Safely | Today.' The imagery of a doctor holding a tablet reinforces the mobile-first, digital nature of the service. It immediately establishes the sector (Healthtech) and the core value proposition (speed and safety).

Slide 2: Key Issues to Impactful Operations

This slide serves as the 'Problem' slide, though it frames issues as operational hurdles. It lists safeguarding staff, burn rate, and cost minimization as primary concerns. The quote at the bottom, 'The health sector must behave like startups,' suggests that VIOS views its role not just as a software provider, but as an operational consultant enabling agility in a traditionally slow-moving industry.

Slide 3: Market Context and Growth

VIOS uses a bar chart to show internet subscription growth, citing a 19.4% average annual growth rate since 2012. The value reaches 87.7 by June 2018. The slide adds a qualitative note that 2020 saw 'triple the growth in online activity,' specifically for healthcare products. This slide attempts to validate the 'Why Now?' by showing that the infrastructure (internet access) and consumer behavior (online searches) have reached a tipping point.

Slide 4: Key Outputs - Telemedicine System

This slide functions as the 'Solution' or 'Value Proposition' slide. It uses a simple 'down arrow' for costs and a 'checkmark' for gains. It claims to decrease operational expenses, travel time, accommodation, exposure risks, and insurance premiums. Conversely, it claims to increase operations expansion, value activities, integrations, R&D, and innovation. It is a high-level summary of the ROI for a healthcare provider using the system.

Slide 5: Technical Capacity

The 'Product' slide lists nine specific features. Notable inclusions are 'Encrypted Secure remote login' and 'Mobile financial services.' The latter is particularly interesting as it suggests VIOS handles the billing or payment aspect of the consultation, which is a significant friction point in telehealth. The mention of 'Attendance tracking' and 'Automated session recording' indicates a focus on compliance and record-keeping.

Slide 6: Current User Traction

This is the most data-dense slide in the deck. It covers the period from October 2019 to March 2020. It reports 170+ registered doctors, with 84 verified and 46 active. It also claims 2,400+ patient profiles and 5-8 daily engagements. However, the footnote is a critical piece of honesty: 'Due to current situation, these users are dormant in vios 1.0 platform waiting for vios 2.0 integration.' This tells an investor that while there is a lead list, the current product is in a state of flux.

Slide 7: B2B Partnership

Slide 7 highlights a partnership between 'ViOS - Orbis' for telehealth development. While it doesn't detail the terms of the partnership, the inclusion of a B2B partner name is intended to provide third-party validation and a potential channel for customer acquisition.

Slide 8: Healthtech Beyond the Pandemic

This slide addresses the long-term viability of the business. It argues that the platform will remain relevant by providing real-time impact data for fundraising, enhanced oversight, and brand retention. It attempts to move the narrative away from a 'pandemic-only' tool to a permanent piece of healthcare infrastructure.

Slide 9: Investment Proposal & Support Requirements

The 'Ask' slide is very specific. VIOS is seeking $120,000 for 15% equity. The list of requirements includes both capital uses (SaaS upgrades, server support, cybersecurity) and 'soft' needs (mentorship, leadership training). This suggests a first-time founder or a very early-stage team looking for an incubator-style relationship rather than just a silent check.

Slide 10: Contact Information

The deck concludes with a contact email and website URL. The branding is consistent with the rest of the deck—clean, white, and professional.

What Works in This Deck

Clear Traction Metrics: Slide 6 provides a transparent breakdown of registered vs. active doctors. The honesty regarding the 'dormant' status of users due to the 2.0 integration builds trust with potential investors. · Specific Technical List: Slide 5 avoids vague buzzwords and lists actual features like 'Mobile financial services' and 'Attendance tracking,' which helps an investor understand the product's scope. · Reasonable Ask: The $120,000 ask is modest and aligned with the reported traction and the 'support requirements' listed. It doesn't overreach for a pre-seed round.

What is Missing

Team Slide: In the provided 10-slide sample, there is no information about the founders' backgrounds. In a pre-seed round, the team is often the most important factor. · Competitor Analysis: The telehealth space is crowded. The deck does not explain how VIOS differentiates itself from major players or local competitors. · Business Model: While 'Mobile financial services' are mentioned, the deck does not explicitly state how VIOS makes money (e.g., per-consultation fee, monthly SaaS subscription, or a percentage of billings). · Unit Economics: There is no mention of Customer Acquisition Cost (CAC) or Lifetime Value (LTV), which are standard for a SaaS teardown.

What a Founder Should Copy

The 'Key Outputs' Format: Slide 4 is an excellent way to visually represent the dual benefit of cost reduction and value creation. It is easy to read and digest in seconds. · The Traction Footnote: If your product is undergoing a major pivot or upgrade that has caused a temporary dip in activity, be upfront about it like VIOS is on Slide 6. Investors will find it anyway during due diligence. · Combining Capital and Mentorship: If you are a first-time founder, explicitly asking for 'Leadership training' and 'Mentorship' as VIOS does on Slide 9 can attract the right kind of 'smart money' investors who enjoy a hands-on approach.

Frequently asked questions

What is the current valuation of VIOS based on this deck?: Based on Slide 9, VIOS is asking for $120,000 in exchange for 15% equity. This calculation suggests a pre-money valuation of approximately $680,000 and a post-money valuation of $800,000. This is a typical range for a pre-seed startup with early traction but a product still in the integration phase.
How many active users does the platform currently have?: According to Slide 6, the platform has 170+ registered doctors, but only 46 are listed as 'Active Doctor profiles.' Additionally, there are 2,400+ patient profiles. However, a footnote indicates these users are currently dormant while waiting for the ViOS 2.0 integration, suggesting the platform is in a transition period.
What specific problems does VIOS aim to solve for doctors?: Slide 4 and Slide 8 outline the core benefits: reducing operational expenses, travel time, and exposure risks. It also aims to help healthcare providers manage 'burn rate' and establish 'safe secure scalable operations.' The goal is to make the health sector behave more like a startup in terms of efficiency.
What technical capabilities are built into the VIOS platform?: Slide 5 lists several 'Technical Capacity' features including end-to-end user profile generation, encrypted login, on-demand video call initiation, attendance tracking, automated session recording, a data cloud link, text functions for prescriptions, and mobile financial services.
What are the primary uses of the requested $120,000 investment?: Slide 9 specifies that the funds and support will be directed toward SaaS upgrades, high-fidelity server support, cybersecurity infrastructure, and co-branding campaigns. The founders also explicitly request mentorship and leadership training as part of the investment package.

Cover slide of the VIOS pitch deck — Pre-Seed 2020 — VIOS pitch deck, slide 1 (2020)

VIOS pitch deck: the facts

Company: VIOS
Year: 2020 (based…
Stage: Pre-Seed
Slides: 29
Sector: Healthtech SaaS
Deck type: Investment Pitch

VIOS pitch deck PDF

The full VIOS deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the VIOS (The VIOS Clinic / ViOS) pitch deck was used for

This deck is a 29‑slide pre‑seed pitch from around mid‑2020 for **VIOS (The VIOS Clinic / ViOS)**, a Delaware‑incorporated telehealth SaaS startup that offers a video‑based telemedicine platform connecting patients to specialist physicians via remote consultations. The deck positions ViOS as a healthtech software‑as‑a‑service and enterprise telehealth infrastructure provider, with separate ViOS Doctor and ViOS Patient apps enabling on‑demand, 20‑minute video consultations and a transaction‑fee business model. It was used to support an early funding ask of **$120,000 for 15% equity** to build out video MVP, server infrastructure, cybersecurity, and B2B access, during the COVID‑19 period when the company emphasized its role in facilitating safe, remote specialist care.

Business model: Telehealth **software-as-a-service** and direct-to-consumer telemedicine platform connecting patients with certified specialist physicians via video consultations, operating as a management services organization (MSO) that provides non‑clinical administrative and managerial infrastructure for independent physician practices.

Headquarters: Middletown, Delaware, United States (651 N Broad St., Suite 206, Middletown, DE 19709).
Industry: Telehealth / Healthtech SaaS / Digital Health.

Round: Pre‑Seed (early telehealth SaaS and telemedicine MVP stage around mid‑2020).

Year: 2020 (deck dated July 2020 and aligned with company incorporation in June 2020).

Raising: USD $120,000 for 15% equity as proposed in the deck’s investment section.

Founded: 2020 (incorporated in Delaware, USA in June 2020).

Use of funds as presented: High‑level categories listed in the deck include mentorship, leadership training, B2B access points, high‑fidelity server support, SaaS upgrades, cyber‑security infrastructure, and co‑branding campaigns.

What the VIOS (The VIOS Clinic / ViOS) deck got right

Concrete product definition with clear telemedicine workflow. The deck clearly describes **ViOS as an end‑to‑end video telemedicine platform** with on‑demand On‑Duty Video Consultation and separate doctor and patient apps, demonstrating a specific product vision rather than a vague concept.
Transparent transaction‑based revenue model. A **20% transaction fee** on specialist‑set consultation prices (with example rates for cardiology, nephrology, pediatrics) provides a transparent and easily understandable business model.
Strong problem framing in the context of COVID‑19. The deck situates ViOS within the **COVID‑19 context**, explicitly referencing reduced medical activity and the need for safe, remote consultations, which strengthens the problem‑solution fit for telehealth adoption.
Differentiation via specialist‑focused telemedicine. By focusing on **specialist and tertiary care for chronic conditions**, with examples of cardiologists, nephrologists, and pediatricians, ViOS differentiates itself from generic telehealth urgent‑care offerings.
Defined geographic and market focus for direct‑pay telehealth. The deck includes **specific geographic opportunities** (India, Pakistan, Nepal, Maldives and global markets), suggesting a clear understanding of where direct‑pay telehealth for specialists may be most feasible.
Early traction evidence available in related materials. Supplementary materials (like the VIOS 2.0 deck) show early traction metrics such as registered doctors and patient profiles, which can be used to support the main fundraise narrative even if they are not deeply integrated in this specific deck.

What could have been stronger

Limited clarity on valuation and capital deployment. The deck requests **$120,000 for 15% equity** but does not provide a clear capitalization table, runway projection, or detailed use‑of‑funds breakdown beyond high‑level items like mentorship, server support, and cybersecurity, making it difficult for investors to assess valuation logic and capital efficiency.
Regulatory and cross‑border compliance under‑explained. Although the deck describes the platform as HIPAA‑compliant, data‑secure, and suitable for multiple countries (e.g., India, Pakistan, Nepal, Maldives), it does not clearly map out the regulatory and licensing requirements for telemedicine across these jurisdictions or address how cross‑border care and specialty licensing will be handled.
Sparse unit economics and integrated traction story. The business model section lists example specialist prices and a 20% platform fee, but offers limited quantitative analysis of customer acquisition cost, expected consultation volume, or cohort retention; traction metrics like registered doctors and patient profiles are mentioned in a separate deck rather than fully integrated into this fundraise narrative.
Broad positioning across multiple business lines without prioritization. The deck positions ViOS simultaneously as a direct‑to‑consumer telehealth marketplace, an enterprise SaaS telemedicine infrastructure provider, and a management services organization for independent practices, but does not deeply prioritize or sequence these segments, potentially blurring strategic focus for early investors.

How an investor would read this deck

What draws attention

Relatively **small pre‑seed ask** (USD $120,000 for 15% equity) suggests a lean capital plan, potentially attractive for angel investors seeking capital efficiency in an early telehealth play.
Clear **transaction‑fee business model** with specialist‑set pricing and a 20% take‑rate enables straightforward revenue modeling once usage data is available.
During COVID‑19, the emphasis on safe, remote specialist consultations for chronic and tertiary care aligns with global telehealth tailwinds and the need to offload in‑person systems.
The combination of a Delaware incorporation with a globally oriented telehealth platform and MSO structure could appeal to investors interested in cross‑border digital health and direct‑pay membership models.

Risks that stand out

Telehealth and digital health are highly competitive, with many established platforms offering virtual specialist access; without strong distribution or partnerships, ViOS risks being commoditized.
Operating across multiple jurisdictions for specialist care introduces regulatory risks related to licensure, data protection, and telemedicine practice laws, which the deck does not fully address.
The platform’s direct‑pay model targets patients who can afford out‑of‑pocket specialist care, potentially limiting addressable market segments compared with insurance‑integrated or employer‑sponsored telehealth solutions.

Questions this deck invites

Can the company provide verifiable data on completed consultations, active paying patients, repeat usage, and revenue since the time of the deck, beyond counts of registered doctors and patient profiles?
How has ViOS navigated regulatory requirements for telemedicine and cross‑border care (licensure, malpractice coverage, data localization) in its key target markets such as the US, South Asia, and other geographies?
What is the current product roadmap for ViOS Doctor and ViOS Patient apps, and how mature is the platform in terms of uptime, security certifications, and integrations with EMR or billing systems?
How does ViOS plan to differentiate and defend against larger telehealth and virtual clinic platforms that also offer specialist access and chronic disease management, especially in the US and South Asian markets?
What is the updated ownership structure and funding history (including any founder financing or angel checks), and how has the company deployed capital relative to the initial $120,000 ask outlined in the deck?

What founders can take from the VIOS (The VIOS Clinic / ViOS) deck

Anchoring a **modest fundraising ask** ($120,000 for 15% equity) to specific infrastructure and support needs can signal capital discipline for an early‑stage telehealth SaaS startup.
Presenting **concrete pricing examples** for different specialists and a fixed platform take‑rate (20%) helps investors quickly understand the unit‑level revenue model in a marketplace‑style telehealth product.
Emphasizing **COVID‑19 context** and the reduction in in‑person care can effectively frame the urgency and relevance of a telemedicine solution, particularly for specialist and tertiary care.
Articulating multiple roles—marketplace, SaaS infrastructure, and MSO—can showcase versatility but also underscores the importance of clearly prioritizing the initial beachhead market for early execution.
Supporting the deck with an additional traction‑oriented presentation (like the VIOS 2.0 deck showing doctor and patient counts) illustrates how separate materials can complement a fundraising pitch by providing deeper operational detail.
Including direct contact information (website, email) and highlighting Delaware incorporation and MSO positioning can reassure investors about corporate structure and go‑to‑market seriousness in regulated healthcare.

VIOS (The VIOS Clinic / ViOS) pitch deck: common questions

What is ViOS / The VIOS Clinic?

ViOS (also branded as **The VIOS Clinic**) is a telehealth platform and healthtech SaaS company that connects patients with certified and licensed specialist physicians for non‑emergency, video‑based consultations via a cash‑pay, direct‑to‑consumer model. It operates both as a telemedicine marketplace (ViOS Doctor and ViOS Patient apps) and as a management services organization (MSO) that provides non‑clinical administrative infrastructure to independent physician practices.

How does ViOS make money?

According to the pitch deck, ViOS planned to charge a **20% transaction fee** on each consultation, with specialists setting their own prices (example pricing: cardiologist $125, nephrologist $100, pediatrician $86 for a 20‑minute consult). External write‑ups describe that patients purchase 20‑minute video sessions via digital payments, while doctors choose consultation fees within a specified range (e.g., USD $70–$110 per session) upon registration.

How much was ViOS trying to raise with this pitch deck?

The deck’s investment proposal requested **$120,000 in exchange for 15% equity**, alongside non‑capital support such as mentorship, leadership training, B2B access, server capacity, SaaS upgrades, cybersecurity infrastructure, and co‑branding campaigns. There is no publicly available confirmation that this specific pre‑seed raise closed or on what terms.

Who is ViOS’s target customer?

ViOS positions itself primarily for **patients with chronic or complex conditions** who need access to specialist physicians (cardiology, nephrology, pediatrics, and other tertiary care specialties) and who can pay out‑of‑pocket for direct telehealth services. The platform targets markets such as South Asia (including India, Pakistan, Nepal, Maldives) and global patients seeking expert second opinions and concierge‑style chronic disease management.

What traction and progress had ViOS achieved around the time of this deck?

The deck indicates that a **video telemedicine MVP** was under development for a July release in 2020, with an end‑to‑end video telemedicine platform and on‑demand On‑Duty Video Consultation. A separate 2020 deck (VIOS 2.0) cites early traction such as over 170 registered doctors and 2,300 patient profiles, but there are no widely published institutional funding announcements; most external profiles emphasize founder‑funding and small‑scale hiring rather than large rounds.